Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Outpatient Study

NCT06335407 is registered in ClinicalTrials.gov with Pharmacotherapies for Alcohol and Substance Use Disorders Alliance as lead sponsor.

NCT NCT06335407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06335407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Outpatient Study
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Phase
Phase 1
Overall status
Recruiting
Start date
July 28, 2025
Completion date
April 30, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder (aud), post traumatic stress disorder (ptsd)